LDN and Menstruation/Ovulation cycles

[Guest guest]

To the Ladies.

I Hope this helps.

Obstetrics & Gynecology 1990;76:1115-1120

© 1990 by The American College of Obstetricians and Gynecologists

Naltrexone in functional hypothalamic amenorrhea and in the normal

luteal phase

V Remorgida, PL Venturini, P Anserini, E Salerno, and L De Cecco

Fifteen young women with a diagnosis of secondary hypothalamic

amenorrhea of at least 2 years' duration were given either 50 mg

naltrexone daily or placebo, following a randomized double-blind

crossover scheme. Seven patients did not menstruate with either

therapy. In the other eight, the following results were recorded (mean

+/- SD and range): a cycle length of 28.7 +/- 7.6 (12-45) days for

naltrexone compared with 30.8 +/- 5.9 (16-43) days for placebo, a

follicular phase length of 20.8 +/- 5.4 (14-34) days for naltrexone and

23.2 +/- 4.3 (19-32) days for naltrexone and 8.3 +/- 1.6 (5-10) days

for placebo. The number of ovulatory cycles was 18 of 24 (75%) with

naltrexone and eight of 24 (33%) with placebo (P less than .05). Most

luteal phases were short. In five normally menstruating women, we gave

either naltrexone or placebo in the luteal phase using a crossover

blinded scheme. Steroidogenesis in the normal luteal phase was not

impaired by naltrexone therapy. In functional hypothalamic amenorrheic

patients with normal weight, menstruation might be restored by either

placebo or naltrexone, but naltrexone provides a clinical and

therapeutic advantage by increasing the ovulation rate.

[Guest guest]

Thanks I appreciate it! When my brain wakes up I will try and

decipher it ;op

Take Care

> To the Ladies.

>

> I Hope this helps.

>

>

>

> Obstetrics & Gynecology 1990;76:1115-1120

> © 1990 by The American College of Obstetricians and Gynecologists

>

>

> Naltrexone in functional hypothalamic amenorrhea and in the normal

> luteal phase

> V Remorgida, PL Venturini, P Anserini, E Salerno, and L De

Cecco

>

>

> Fifteen young women with a diagnosis of secondary hypothalamic

> amenorrhea of at least 2 years' duration were given either 50 mg

> naltrexone daily or placebo, following a randomized double-blind

> crossover scheme. Seven patients did not menstruate with either

> therapy. In the other eight, the following results were recorded

(mean

> +/- SD and range): a cycle length of 28.7 +/- 7.6 (12-45) days for

> naltrexone compared with 30.8 +/- 5.9 (16-43) days for placebo, a

> follicular phase length of 20.8 +/- 5.4 (14-34) days for

naltrexone and

> 23.2 +/- 4.3 (19-32) days for naltrexone and 8.3 +/- 1.6 (5-10)

days

> for placebo. The number of ovulatory cycles was 18 of 24 (75%)

with

> naltrexone and eight of 24 (33%) with placebo (P less than .05).

Most

> luteal phases were short.

[Guest guest]

,

Looks like some of what I posted was cut off. The last sentence is key.

Fifteen young women with a diagnosis of secondary hypothalamic

amenorrhea of at least 2 years' duration were given either 50 mg

naltrexone daily or placebo, following a randomized double-blind

crossover scheme. Seven patients did not menstruate with either

therapy. In the other eight, the following results were recorded (mean

+/- SD and range): a cycle length of 28.7 +/- 7.6 (12-45) days for

naltrexone compared with 30.8 +/- 5.9 (16-43) days for placebo, a

follicular phase length of 20.8 +/- 5.4 (14-34) days for naltrexone and

23.2 +/- 4.3 (19-32) days for naltrexone and 8.3 +/- 1.6 (5-10) days

for placebo. The number of ovulatory cycles was 18 of 24 (75%) with

naltrexone and eight of 24 (33%) with placebo (P less than .05). Most

luteal phases were short. In five normally menstruating women, we gave

either naltrexone or placebo in the luteal phase using a crossover

blinded scheme. Steroidogenesis in the normal luteal phase was not

impaired by naltrexone therapy. In functional hypothalamic amenorrheic

patients with normal weight, menstruation might be restored by either

placebo or naltrexone, but naltrexone provides a clinical and

therapeutic advantage by increasing the ovulation rate.

On Feb 26, 2006, at 9:26 PM, wrote:

> Thanks I appreciate it!  When my brain wakes up I will try and

> decipher it ;op

>

> Take Care

>

> > To the Ladies.

> >

> > I Hope this helps.

> >

> >

> >

> > Obstetrics & Gynecology 1990;76:1115-1120

> > © 1990 by The American College of Obstetricians and Gynecologists

> >

> >

> > Naltrexone in functional hypothalamic amenorrhea and in the normal

> > luteal phase

> > V Remorgida,  PL Venturini,  P Anserini,  E Salerno, and  L De

> Cecco

> >

> >

> >   Fifteen young women with a diagnosis of secondary hypothalamic

> > amenorrhea of at least 2 years' duration were given either 50 mg

> > naltrexone daily or placebo, following a randomized double-blind

> > crossover scheme. Seven patients did not menstruate with either

> > therapy. In the other eight, the following results were recorded

> (mean

> > +/- SD and range): a cycle length of 28.7 +/- 7.6 (12-45) days for

> > naltrexone compared with 30.8 +/- 5.9 (16-43) days for placebo, a

> > follicular phase length of 20.8 +/- 5.4 (14-34) days for

> naltrexone and

> > 23.2 +/- 4.3 (19-32) days for naltrexone and 8.3 +/- 1.6 (5-10)

> days

> > for placebo. The number of ovulatory cycles was 18 of 24 (75%)

> with

> > naltrexone and eight of 24 (33%) with placebo (P less than .05).

> Most

> > luteal phases were short.

>

>

>

>

>

>

[Guest guest]

Believe it or not I was researching this last night and read the paragraph you missed . I also read at a few places that the birth control pill should not be taken with naltrexone. Only it didn't give a reason why . I hate that!

Thanks for posting the rest tho!

Take Care >> ,> > Looks like some of what I posted was cut off. The last sentence is key.> > > > Fifteen young women with a diagnosis of secondary hypothalamic > amenorrhea of at least 2 years' duration were given either 50 mg > naltrexone daily or placebo, following a randomized double-blind > crossover scheme. Seven patients did not menstruate with either > therapy. In the other eight, the following results were recorded (mean > +/- SD and range): a cycle length of 28.7 +/- 7.6 (12-45) days for > naltrexone compared with 30.8 +/- 5.9 (16-43) days for placebo, a > follicular phase length of 20.8 +/- 5.4 (14-34) days for naltrexone and > 23.2 +/- 4.3 (19-32) days for naltrexone and 8.3 +/- 1.6 (5-10) days > for placebo. The number of ovulatory cycles was 18 of 24 (75%) with > naltrexone and eight of 24 (33%) with placebo (P less than .05). Most > luteal phases were short. In five normally menstruating women, we gave > either naltrexone or placebo in the luteal phase using a crossover > blinded scheme. Steroidogenesis in the normal luteal phase was not > impaired by naltrexone therapy. In functional hypothalamic amenorrheic > patients with normal weight, menstruation might be restored by either > placebo or naltrexone, but naltrexone provides a clinical and > therapeutic advantage by increasing the ovulation rate.> >